Athira Pharma, Inc. – NASDAQ:ATHA

Add to watchlist

$0.398

-0.15

-27.55%

Market closed

Open in about 5 hours

-83.43%

month

-83.43%

quarter

-76.19%

year

Market Cap	21.19M
Enterprise value	1.03M

P/E	-1.04
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	0.40
PEG ratio	0.01
EPS	-3.05

Revenue	N/A
EBITDA	-124.28M
Income	-116.18M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Athira Pharma, Inc. (NASDAQ:ATHA): Profit margin
Jun 2023	0	-29.59M
Sep 2023	0	-32.97M
Dec 2023	1.65M	-27.28M	-1647.64%
Mar 2024	0	-26.33M

Athira Pharma Financials Estimate

Q Y

Athira Pharma, Inc. (NASDAQ:ATHA): Analyst Estimates
Dec 2023	1.65M	-27.28M	-1647.64%
Mar 2024	0	-26.33M
Oct 2025	0	-35.63M
Dec 2025	0	-34.87M

Analysts Price target
Financials & Ratios estimates

Athira Pharma, Inc. (NASDAQ:ATHA): Debt to assets
Jun 2023	208048000	23.06M	11.09%
Sep 2023	184700000	29.93M	16.21%
Dec 2023	160245000	30.05M	18.76%
Mar 2024	133458000	26.71M	20.02%

Athira Pharma, Inc. (NASDAQ:ATHA): Cash Flow
Jun 2023	-24.28M	32.48M	242K
Sep 2023	-23.98M	20.69M	0
Dec 2023	-26.29M	6.39M	152K
Mar 2024	-25.80M	13.04M	0

Athira Pharma alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Athira Pharma, Inc. (NASDAQ:ATHA): Employee count
Aug 2023	63
Sep 2023	63
Oct 2023	63
Nov 2023	63
Dec 2023	63
Jan 2024	63
Feb 2024	63
Mar 2024	65
Apr 2024	65
May 2024	65
Jun 2024	65
Jul 2024	65

Athira Pharma
Hedge Funds Holdings Q1 2023

23.67% -38.96%

of ATHA is owned by hedge funds

46 -47

hedge funds hold ATHA stock

8.93M -14.75M

shares is hold by hedge funds

ATHA hedge funds holdings changes

Athira Pharma, Inc. (NASDAQ:ATHA): Insider trades (number of shares)
Period	Buy	Sel
Mar 2023	30000	0
Jun 2023	80012	0
Dec 2023	605686	0
Jan 2024	0	13264

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	5 Jan 2024	LITTON MARK JAMES director, officer: Chief Executive Officer director, officer: Chief Execut..	Common Stock	4,820	$2.91	$14,026
Sale	5 Jan 2024	WORTHINGTON MARK officer: General Counsel officer: General Counsel	Common Stock	2,412	$2.91	$7,019
Sale	5 Jan 2024	LENINGTON RACHEL officer: Chief Operating Officer officer: Chief Operating Officer	Common Stock	2,412	$2.91	$7,019
Sale	5 Jan 2024	GENGOS ANDREW officer: CFO AND CHIEF BUSINESS OFFICER officer: CFO AND CHIEF BUSINESS..	Common Stock	1,208	$2.91	$3,515
Sale	5 Jan 2024	CHURCH KEVIN officer: CHIEF SCIENTIFIC OFFICER officer: CHIEF SCIENTIFIC OFFICER	Common Stock	2,412	$2.91	$7,019
Purchase	29 Dec 2023	PERCEPTIVE ADVISORS LLC director, 10 percent owner: director, 10 percent owner:	Common Stock	163,954	$2.38	$390,211
Purchase	28 Dec 2023	PERCEPTIVE ADVISORS LLC director, 10 percent owner: director, 10 percent owner:	Common Stock	409,598	$2.44	$999,419
Purchase	27 Dec 2023	PERCEPTIVE ADVISORS LLC director, 10 percent owner: director, 10 percent owner:	Common Stock	32,134	$2.28	$73,266
Purchase	7 Jun 2023	GENGOS ANDREW officer: See Below officer: See Below	Common Stock	422	$3.36	$1,417
Purchase	7 Jun 2023	GENGOS ANDREW officer: See Below officer: See Below	Common Stock	2,859	$3.4	$9,721

Athira Pharma
Earnings Call Transcripts

Quarter	Transcript
Q4 2021 24 Mar 2022	Q4 2021 Earnings Call Transcript

ATHA earnings call transcripts

Athira Pharma
Executives

Insider	Age	Since	Compensation
Dr. Hans Moebius (1957) Chief Medical Officer	68		$425,060
Ms. Glenna K. Mileson (1959) Chief Financial Officer & Corporation Sec.	66		$417,640

Athira Pharma
Latest News

Friday, 6 December 2024
17:30	Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND	globenewswire.com
Thursday, 5 December 2024
09:40	ATHA Energy identifies high-grade uranium mineralization in new outcrops at Angilak	proactiveinvestors.com
Monday, 25 November 2024
09:39	ATHA Energy reveals updated technical report for Angilak uranium project	proactiveinvestors.com
Thursday, 7 November 2024
16:05	Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates	globenewswire.com
Tuesday, 29 October 2024
09:09	ATHA Energy appoints seasoned experts to leadership team	proactiveinvestors.com
Friday, 11 October 2024
08:45	ATHA Energy and Terra Uranium enter into strategic option agreements on key uranium projects	proactiveinvestors.com
07:00	ATHA Energy Announces Option Agreements With Terra Uranium for Spire, Horizon, and Pasfield Projects	globenewswire.com
Thursday, 10 October 2024
10:09	ATHA Energy CEO highlights 2024 growth priorities at TD Securities Nuclear Roundtable	proactiveinvestors.com
Thursday, 19 September 2024
08:28	ATHA Energy secures entire Lac 50 structural corridor at Angilak uranium project	proactiveinvestors.com
Tuesday, 17 September 2024
11:59	Athira Pharma laying off 49 employees, about 70% of workforce, as part of restructuring	geekwire.com
09:00	Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases	globenewswire.com
Wednesday, 4 September 2024
12:35	ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal	zacks.com
08:48	Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks	benzinga.com
Tuesday, 3 September 2024
16:13	Athira Pharma's Alzheimer's drug fails in mid-to-late stage trial	reuters.com
16:01	Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease	globenewswire.com
09:47	ATHA Energy identifies new mineralized trends at Angilak uranium project	proactiveinvestors.com
Wednesday, 28 August 2024
08:41	ATHA Energy advances exploration at Gemini and Angilak uranium projects	proactiveinvestors.com
Friday, 23 August 2024
10:41	Are Medical Stocks Lagging Athira Pharma (ATHA) This Year?	zacks.com
Tuesday, 20 August 2024
08:49	ATHA Energy signs LOI for joint venture on Canadian uranium projects	proactiveinvestors.com
07:00	ATHA Energy Announces Proposed Option Agreements with Terra Uranium for Spire, Horizon, and Pasfield Projects	globenewswire.com
Wednesday, 7 August 2024
10:40	Is Athira Pharma (ATHA) Stock Outpacing Its Medical Peers This Year?	zacks.com
Thursday, 1 August 2024
16:05	Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates	globenewswire.com
Wednesday, 31 July 2024
08:05	Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology at the Alzheimer's Association International Conference (AAIC) 2024	globenewswire.com
Wednesday, 10 July 2024
09:56	Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up	zacks.com
08:51	ATHA Energy expands uranium footprint at Angilak	proactiveinvestors.com
07:00	ATHA Energy Angilak 2024 Exploration Update: First Six Holes Successfully Expand Footprint of Uranium Mineralization With 100% Hit Rate Outside of Historic Resource	globenewswire.com
Monday, 17 June 2024
09:31	ATHA Energy director's machine learning innovation recognized by Future Explorer's Competition	proactiveinvestors.com
Wednesday, 12 June 2024
07:00	Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients	globenewswire.com
Monday, 10 June 2024
08:00	Glancy Prongay & Murray LLP and Labaton Keller Sucharow LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of the Publicly Traded Common Stock of Athira Pharma, Inc. - (NASDAQ: ATHA)	prnewswire.com
Monday, 3 June 2024
09:53	ATHA Energy commences 2024 Angilak diamond drilling program	proactiveinvestors.com

Ideas & Opinions

Seeking Alpha 2 Nov 2022

Trading Ideas On The Upcoming CTAD 2022 Conference
Seeking Alpha 20 Oct 2022

Athira Pharma: Fosgonimeton May Outperform Lecanemab In Alzheimer's
Seeking Alpha 18 Oct 2022

An Overview Of Today's Alzheimer's Disease Development Field
Seeking Alpha 22 Jun 2022

Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug
Seeking Alpha 2 Jun 2022

Anavex's Blarcamesine: Why It May Treat Alzheimer's Disease
Seeking Alpha 19 Apr 2022

Pathways Impacting Alzheimer's Disease Drug Development
Seeking Alpha 30 Jun 2021

Athira Pharma - ATH-1017: Panacea Or Pandora's Box?
Seeking Alpha 16 Jun 2021

Synaptogenix: The Next Big Thing In Alzheimer's

Frequently Asked Questions (FAQ)

What's the price of Athira Pharma stock today?

One share of Athira Pharma stock can currently be purchased for approximately $0.4.
When is Athira Pharma's next earnings date?

Unfortunately, Athira Pharma's (ATHA) next earnings date is currently unknown.
Does Athira Pharma pay dividends?

No, Athira Pharma does not pay dividends.
How much money does Athira Pharma make?

Athira Pharma has a market capitalization of 21.19M.
What is Athira Pharma's stock symbol?

Athira Pharma, Inc. is traded on the NASDAQ under the ticker symbol "ATHA".
What is Athira Pharma's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Athira Pharma?

Shares of Athira Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Athira Pharma's key executives?
Athira Pharma's management team includes the following people:
- Dr. Hans Moebius Chief Medical Officer(age: 68, pay: $425,060)
- Ms. Glenna K. Mileson Chief Financial Officer & Corporation Sec.(age: 66, pay: $417,640)
How many employees does Athira Pharma have?

As Jul 2024, Athira Pharma employs 65 workers.
When Athira Pharma went public?

Athira Pharma, Inc. is publicly traded company for more then 4 years since IPO on 18 Sep 2020.
What is Athira Pharma's official website?

The official website for Athira Pharma is athira.com.
Where are Athira Pharma's headquarters?

Athira Pharma is headquartered at 18706 North Creek Parkway, Bothell, WA.
How can i contact Athira Pharma?

Athira Pharma's mailing address is 18706 North Creek Parkway, Bothell, WA and company can be reached via phone at 425 620 8501.

Athira Pharma, Inc.

athira.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

425 620 8501

18706 North Creek Parkway
Bothell, WA 98011

CIK: 0001620463
ISIN: US04746L1044
CUSIP: 04746L104